Case ReportsClinical Response to Thalidomide in the Treatment of Intracranial Tuberculomas: Case Reportde la Riva, Patricia MD*; Urtasun, Miguel MD, PhD*; Castillo-Trivino, Tamara MD*; Camino, Xabier MD†; Arruti, Maialen MD*; Mondragón, Elisabet MD*; de Munain, Adolfo Lopez MD, PhD*‡§∥Author Information *Department of Neurology, Universitary Hospital of Donostia, San Sebastian, Spain, †Department of Infectious Diseases, Universitary Hospital of Donostia, San Sebastian Spain; ‡Biomedical Network Research Centre for Neurodegenerative Diseases (CIBERNED–Instituto de Salud Carlos III), Spain; §Neuroscience Area, Institute Biodonostia, San Sebastian, Spain; and ∥Department of Neurosciences, University of Basque Country (UPV-EHU), San Sebastian, Spain. Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. Address correspondence and reprint requests to Patricia de la Riva, MD, Department of Neurology, Universitary Hospital of Donostia, Paseo Dr. Beguiristain 109, 20014 Donostia, Gipuzcoa, Spain; E-mail: firstname.lastname@example.org Clinical Neuropharmacology: March/April 2013 - Volume 36 - Issue 2 - p 70-72 doi: 10.1097/WNF.0b013e318285caa1 Buy Metrics Abstract We describe a patient with multiple intracranial tuberculomas resistant to standard care with antituberculosis drugs and corticosteroids who responded well to thalidomide. Adjunctive thalidomide may have a role in the management of refractory intracranial tuberculomas, although it should be used conservatively owing to its potential adverse events. © 2013 Lippincott Williams & Wilkins, Inc.